rBCG vaccine secreting SARS-CoV-2 antigens

rBCG vaccine project
|

Aim: Mycobacterium bovis BCG is a live attenuated vaccine that is used since almost 100 years for the vaccination against tuberculosis, with a solid safety record in billions of immunocompetent individuals. The aim of the project is to construct recombinant BCG strains that express viral protein(s) of the SARS-CoV-2 virus in fusion with the 6 kD early secreted antigenic target (ESAT-6), secreted by the type VII secretion systems.

Back to top